Petronas Agrees Partnership to Develop oil Industry Chemicals

Home > News >Latest > Petronas agrees partnership to develop oil industry chemicals

Petronas agrees partnership to develop oil industry chemicals PETRONAS Chemicals Group (PCG) and Scomi Energy Services have agreed to work together to research, develop and sell chemicals for the oil and gas sectors. The agreement formalises an existing R&D partnership started in 2016 aimed at developing chemicals for the oil and gas industry; and adds a second agreement to commercialise a water-based mud additive used to improve shale inhibition during drilling. PCG CEO Datuk Sazali Hamzah said: "This partnership is advantageous for both PCG and Scomi, as it enables us to come together in creating innovative and sustainable solutions for our customers".
Speaking to Reuters the day after the deal was announced, Hamzah said that PCG plans to spend around US$6bn over the next 15-20 years expanding its specialty chemicals portfolio through buyouts and partnerships. Hamzah said in May that the firm will diversify its product portfolio into differentiated and specialty chemicals as it bought Dutch specialty chemicals firm Da Vinci Groupfor around US$180m.

Chemify and Prepaire Labs announced to expand their partnership with an additional program to tackle the ongoing Opioid crisis and develop a novel class of digitally discovered non-addictive Opioids as pain modulators, as well as drugs tackling Opioid addiction directly by combining Chemify's breakthrough programmable chemistry platform with Prepaire's integrated novel open collaboration drug discovery platform. The project, named Toxifree, comes in response to the FDA's Center for Drug Evaluation and Research (CDER) requesting drugmakers and researchers to develop treatments for stimulant use disorder, hoping to address a major gap in the addiction crisis response.After a successful initial partnership, Chemify and Prepaire are now aiming to leverage Chemify's Chemputation technology which enables the automated and integrated design, discovery, and synthesis of complex molecules on demand using a chemical programming language and Prepaire's advanced open-architecture drug development platform.Under the terms of this partnership, Chemify will design and discover novel compounds to identify Opioid-derived hits and develop them further into candidates. Chemify will receive at least USD $30 million in payments and pre-negotiated, success-driven clinical and regulatory milestones for each developed molecule, as well as single digit royalties on any resulting products.Lee Cronin, Chemify's Founder and CEO and Regius Professor of Chemistry at the University of Glasgow has extensive experience leading research efforts to develop solutions for the opioid crisis. Cronin lead a team that won several NIH-prize challenges including winning the grand runner up prize for the design, discovery and automated synthesis of next generation, safer and non-addictive drug-candidates to help address the opioid crisis."We are extremely excited to combine Chemify's technology for molecular design, discovery and synthesis with the integrated Prepaire platform to expand our collaboration and create a fully integrated, digitally driven drug discovery approach. With this partnership we are breaking ground on a new pain modulation discovery program that aims to tackle the global need for better and non-addictive pain medication. With our unique design approach guided by Chemputation, we are utilizing an evolutionary approach to discovering novel compounds to solve this devastating and critical healthcare need," said Professor Lee Cronin, Chemify's Founder and CEO."Our partnership with Chemify allows our discovery platform to integrate directly with Chemify's chemical space exploration approach, enabling us to access novel chemical matter that would have otherwise been inaccessible. As we progress our collaboration, we are aiming to build an integrated approach that can be used for many more indications beyond novel pain modulators. There aren't any approved treatments to help address addiction to opioids, whose use has surged in recent years. The purpose of this FDA guidance is to assist in the clinical trial designs for the development of novel drugs to support indications for treatment of moderate to severe cocaine use disorder, treatment of moderate to severe methamphetamine use disorder, or treatment of moderate to severe prescription stimulant use disorder," said Dr Vicent Ribas, Prepaire's Co-Founder.About ChemputationDigital chemistry applies principles of computation to chemistry for programable chemistry and Chemify has developed the underpinning infrastructure to make this possible for chemical discovery and synthesis. Like a computer program, digital chemistry programs can automatically run chemical experiments, make new molecules, and ensure that complex chemical recipes are always accessible and perfectly reproducible. Chemical programs are precise pieces of code that allow fully transparent and reliable operation allowing the implementation of AI and other techniques with full audit and safety.About ChemifyBased in Glasgow, Chemify is a pioneering company digitizing chemistry to provide world-leading pharmaceutical, biotechnology, and industrial partners access to an exponentially growing space of novel molecules and materials. By leveraging decades of chemistry experience, hardware robotics, and artificial intelligence, Chemify's Chemputation technology enables companies to access an end-to-end workflow for drug discovery, molecule synthesis, and materials discovery. Chemify was founded by CEO Lee Cronin based on conceptual advancements from Cronin's Digital Chemistry Laboratory at the University of Glasgow in Scotland. By building the infrastructure to digitize chemistry, Chemify is reimagining chemical research, discovery and manufacturing to benefit all of humanity by accelerating advances across chemistry with a focus on medicine and functional materials.About Prepaire LabsPrepaire Labs is a pioneering healthcare technology company focused on revolutionizing drug discovery and precision medicine. Through the integration of deep learning and biology, Prepaire Labs builds predictive models grounded in genetic, phenotypic, and clinical data. These models form a view to the underlying architecture and biology of diseases. Prepaire Labs utilizes patient-derived induced pluripotent stem cells (iPSCs), genome editing, high-content cellular phenotyping, and machine learning to create in vitro disease models that optimize genetics, cell-type, environment, and multidimensional data collection for increased predictability of human clinical outcomes. A state-of-the-art BSL3 lab is opening in May 2024, located at Masdar City, Abu Dhabi, UAE.

Headquartered in Luxembourg, ChemChain's proprietary IP and technology will bring an expanded, innovative approach to further augment 3E's Supply Chain & Sustainability solution, 3E Exchange. 3E Exchange's unified supply chain platform helps customers organize their global library of supply chain data and streamline workflows in a scalable and compliant manner. Specifically, 3E leverages its market leading digital product passport and renowned regulatory content capabilities to drive best-in-class supply chain management for its growing list of customers. Together, 3E and ChemChain are united in their mission to accelerate global supply chain transparency and sustainability with a unique combination of technology and regulatory expertise."ChemChain and 3E share a vision to create a safer, more sustainable world that protects people, safeguards products, and helps businesses grow," said Greg Gartland, Chief Executive Officer of 3E. "Together with ChemChain, 3E offers an unmatched combination of global regulatory expertise and a cutting-edge platform that dramatically simplifies transferring information along the value chain in a transparent and secure manner. 3E improves cross-functional engagement across global enterprises, and future-proofs products against ever-changing regulations. We look forward to the continued expansion of our supply chain solutions and empowering our clients to further accelerate their sustainability efforts."With 175,000+ supplier relationships across all major geographies, the 3E Exchange platform drives a strong return-on-investment for its customers. Powered by 3E's market leading regulatory expertise covering over 500,000 chemical substances, 3E Exchange enables superior supply chain management while also advancing companies' ESG objectives. Continued momentum towards sustainable supply chains has highlighted that preparing for a circular economy should be a critical component of every company's product strategy.Pete Girard, Managing Director of Supply Chain and Sustainability at 3E, said "The acquisition of ChemChain illustrates our continued focus on supply chain product innovation and thought leadership. The ChemChain team has incubated a novel and tech-forward approach to drive digital product passport adoption, and we look forward to integrating these technologies into 3E Exchange. The highly scalable digital product passport model offers a single source of truth that underpins sustainable supply chain management, while ensuring maximum protection of company trade secrets" added Lorenzo Zullo, Co-Founder and CEO of ChemChain. "As part of 3E, and leveraging tracked experience in end-to-end supply chain transparency across multiple industries, including textile & clothing, furniture, and detergents, ChemChain will accelerate innovation and position customers for success in the face of a highly complex and dynamic global regulatory landscape."ChemChain represents 3E's fourth acquisition announcement since its separation from Verisk in March 2022.Shearman & Sterling LLP served as the legal advisor to 3E . click apply for full job details